2-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-2-ylmethoxy)-9-pyrimidin-5-yl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-2-ylmethoxy)-9-pyrimidin-5-yl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one
• 英文别名: 2-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-2-ylmethoxy)-9-pyrimidin-5-yl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one
• 化学式: C₂₄H₁₉N₅O₄
• 分子量: 441.4
• InChiKey: XFIMSUZLQKFQIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  99
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS)
  申请人：GALAPAGOS NV

  公开号：US20160039807A1

  公开（公告）日：2016-02-11

  A compound according to Formula (Ia), wherein Cy, L 1 , G, and R 1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  根据公式（Ia）描述的化合物，其中Cy，L1，G和R1如本文所述。本发明涉及一种新的化合物，其按照公式（I）拮抗GPR84，一种参与炎症状况的G蛋白偶联受体，并提供制备这些新化合物的方法，包括这些化合物的制药组合物，以及通过给予本发明化合物预防和/或治疗炎症状况（例如炎症性肠病（IBD），类风湿性关节炎，血管炎），肺部疾病（例如慢性阻塞性肺疾病（COPD）和肺间质性疾病（例如特发性肺纤维化（IPF））），神经炎症性状况，感染性疾病，自身免疫性疾病，内分泌和/或代谢性疾病，和/或通过给予本发明化合物来改善免疫细胞功能的疾病。
• COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
  申请人：Galapagos NV

  公开号：EP3710004A1

  公开（公告）日：2020-09-23
• US9708312B2
  申请人：——

  公开号：US9708312B2

  公开（公告）日：2017-07-18
• [EN] NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS)<br/>[FR] NOUVELLES DIHYDROPYRIMIDINOISOQUINOLINONES ET COMPOSITIONS PHARMACEUTIQUES À BASE DE CELLES-CI POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES (ANTAGONISTES DU GPR84)
  申请人：GALAPAGOS NV

  公开号：WO2014095798A1

  公开（公告）日：2014-06-26

  A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.